Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-90
SponsorUniversity of Monastir

About this trial

Congestive heart failure (CHF) remains a major cause of morbidity, rehospitalization, and mortality worldwide, particularly among elderly and polymorbid patients. Systemic congestion is its most characteristic clinical manifestation and the leading cause of hospitalization for acute heart failure. Standard treatment relies on loop diuretics, primarily furosemide, to reduce fluid overload and alleviate congestive symptoms. However, in clinical practice, many patients exhibit an inadequate diuretic response or resistance to furosemide, particularly in the context of cardiorenal syndrome (CRS), where cardiac and renal dysfunction mutually exacerbate each other. This profile, frequently observed in advanced stages of heart failure, significantly limits the effectiveness of guideline-directed medical therapies (GDMTs), particularly SGLT2 inhibitors, mineralocorticoid receptor antagonists, and angiotensin-converting enzyme (ACE) inhibitors, whose use is often restricted by hypotension, hyperkalemia, or impaired renal function.

Thus, in this subgroup of patients, conventional pharmacological approaches encounter a therapeutic barrier, necessitating the search for alternative or complementary strategies targeting sodium and water depletion without compromising renal perfusion. In this context, the combined administration of hypertonic saline (HS) and furosemide has been proposed as a pathophysiologically sound approach to break the vicious cycle of cardiorenal syndrome. Hypertonic saline solution (HSS) acts by restoring effective intravascular volume, improving renal perfusion, and promoting more efficient natriuresis through better furosemide delivery to the distal nephron. Pioneering studies by Paterna et al. showed that the concomitant administration of HSS (1.4-3% NaCl, 150-250 mL) and intravenous furosemide increased diuresis, improved the hemodynamic profile, and reduced the length of hospital stay and readmission rates without deterioration of renal function.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Chronic renal insufficiency (serum creatinine > 150 µg/ml)

Diagnosis of heart failure (preserved or reduced LVEF)

Signed informed consent

Disqualifiers

Severe hyponatremia (<130 mmol/L) or hypernatremia (>150 mmol/L),

History of allergic reaction to HSS or furosemide

Shock or hemodynamic instability

Pregnancy or breastfeeding

Trial design

Design model

Parallel

Treatments tested in this trial

  • Hypertonic sodium chloride 10%

    Drug

    50 mL of 10% hypertonic sodium chloride (NaCl)

  • Sodium Chloride 0.9%

    Drug

    50 mL of 0.9% sodium chloride (NaCl)

  • Furosemide intravenous solution

    Drug

    Furosemide 250 mg administered intravenously over 60 minutes once weekly for 2 months.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: HSS groupExperimental treatment 2 interventions
Group B: placebo groupPlacebo comparator 2 interventions

Trial outcomes

Primary outcomes

1

Number of participants rehospitalized for heart failure

Description: Number of participants requiring rehospitalization for heart failure during follow-up.

Time frame
30 days and 60 days
2

All-cause mortality

Description: Number of deaths from any cause during follow-up.

Time frame
30 days and 60 days

Secondary outcomes

1

Serum creatinine level

Evaluation of serum creatinine levels.

Time frame
30 days 60 days
2

Blood urea level

Evaluation of blood urea levels.

Time frame
30 days 60 days
3

BNP or NT-proBNP concentration

Evaluation of BNP or NT-proBNP levels.

Time frame
30days 60 days
4

Quality of life and patient satisfaction score assessed using a Likert scale

Description: Assessment of quality of life and patient satisfaction using a 5-point Likert scale ranging from 1 to 5, where: 1 = very dissatisfied/very poor quality of life 5 = very satisfied/excellent quality of life Higher scores indicate better patient satisfaction and quality of life.

Time frame
30 days and 60 days

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: